Shanghai, China, 14 February 2025 – MicroPort^® CardioFlow is proud to announce that its second-generation transcatheter aortic valve implantation (TAVI) solution, VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), has received marketing approval from the Central Drugs Standard Control Organization (CDSCO) of India (License No.: IMP/MD/2024/000964).

VitaFlow Liberty^® inherits the advantages of its predecessor, VitaFlow^®, in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and an advanced double-layer PET skirt. These design elements offer strong radial support, improved coaxial deployment, and reduced perivalvular leakage post-procedure. Moreover, its breakthrough next-generation delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

As the world's first electric retrievable TAVI (Transcatheter Aortic Valve Implantation）system, VitaFlow Liberty^®, along with its accessory, the Alwide^® series Balloon Catheter, has been successfully adopted in over 700 leading hospitals across 20 countries and regions, benefiting over 10,000 patients with aortic valve diseases worldwide.

India’s TAVI market reached 3,000 units in 2024 and is expected to grow significantly. The approval of VitaFlow Liberty^® is set to enhance the surgical experience for Indian physicians through its innovative technology, potentially reshaping the competitive landscape of the country’s TAVI market. This milestone also marks a significant step in MicroPort^® CardioFlow’s expansion into the Asian market, bringing new hope to patients with structural heart diseases.